Emerging drugs for coronary restenosis: the role of systemic oral agents the in stent era

ISSN： 1472-8214

Source： Expert Opinion on Emerging Drugs, Vol.14, Iss.4, 2009-12, pp. : 561-576

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Role of drugs in prevention of coronary restenosis

Inpharma, Vol. 1, Iss. 1399, 2003-01 ,pp. : 2-2

Adis International

Access to resources Recommend Favorite

Therapeutic Potential of Oral Antiproliferative Agents in the Prevention of Coronary Restenosis

By Pramod Kuchulakanti Ron Waksman

Drugs, Vol. 64, Iss. 21, 2004-01 ,pp. : 2379-2388

Adis International

Access to resources Recommend Favorite

Sirolimus-eluting stent reduces restenosis, coronary events

Inpharma, Vol. 1, Iss. 1342, 2002-01 ,pp. : 12-12

Adis International

Access to resources Recommend Favorite

Sirolimus-eluting stent superior for coronary artery restenosis prevention

Inpharma, Vol. 1, Iss. 1389, 2003-01 ,pp. : 13-14

Adis International

Access to resources Recommend Favorite

Dexamethasone and Restenosis After Coronary Stent Implantation: New Indication for an Old Drug?

Current Pharmaceutical Design, Vol. 10, Iss. 4, 2004-02 ,pp. : 349-355

Bentham Science Publishers

Access to resources Recommend Favorite